Heidi Greulich

Heidi Greulich

UNVERIFIED PROFILE

Are you Heidi Greulich?   Register this Author

Register author
Heidi Greulich

Heidi Greulich

Publications by authors named "Heidi Greulich"

Are you Heidi Greulich?   Register this Author

49Publications

3197Reads

39Profile Views

Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.

Int J Cancer 2019 Jun 10. Epub 2019 Jun 10.

Department of Nanobiomedical Science, Dankook University, Cheonan, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32499DOI Listing
June 2019

Landscape of genomic alterations in cervical carcinomas.

Nature 2014 Feb 25;506(7488):371-5. Epub 2013 Dec 25.

1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA [3] Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [4].

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature12881DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161954PMC
February 2014

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Cancer Res 2013 Nov 24;73(22):6770-9. Epub 2013 Sep 24.

Authors' Affiliations: Departments of Medical Oncology and Cancer Biology; Center for Cancer Genome Discovery, Lowe Center for Thoracic Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of Medicine, Brigham and Women's Hospital; Departments of Biological Chemistry and Molecular Pharmacology and Pathology, Harvard Medical School, Boston, Massachusetts; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea; and The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903789PMC
November 2013

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.

Front Oncol 2013 23;3:86. Epub 2013 Apr 23.

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA, USA ; Department of Medicine, Harvard Medical School Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632856PMC
May 2013

Targeting mutant fibroblast growth factor receptors in cancer.

Trends Mol Med 2011 May 1;17(5):283-92. Epub 2011 Mar 1.

Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2011.01.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809064PMC
May 2011

Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability.

Mol Cell Biol 2008 Oct 18;28(20):6223-33. Epub 2008 Aug 18.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00658-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577431PMC
October 2008

Somatic mutations affect key pathways in lung adenocarcinoma.

Nature 2008 Oct;455(7216):1069-75

The Genome Center at Washington University, Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63108, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature07423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694412PMC
October 2008

Probing the cancer genome.

Authors:
Heidi Greulich

Genome Biol 2008 15;9(5):309. Epub 2008 May 15.

Dana-Farber Cancer Institute, Binney St, Boston, MA 02115, and Broad Institute of MIT and Harvard, Cambridge Center, Cambridge, MA 02142, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/gb-2008-9-5-309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441462PMC
July 2008

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.

Nucleic Acids Res 2008 Apr 27;36(7):2446-56. Epub 2008 Feb 27.

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkn089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2367734PMC
April 2008

SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.

Genes Chromosomes Cancer 2008 Mar;47(3):253-9

Cancer Biology Program, Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20527DOI Listing
March 2008

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Proc Natl Acad Sci U S A 2008 Feb 28;105(6):2070-5. Epub 2008 Jan 28.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0709662105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538882PMC
February 2008

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.

Cancer Biol Ther 2007 May 13;6(5):661-7. Epub 2007 Feb 13.

Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.6.5.4003DOI Listing
May 2007